GILD
Gilead Sciences, Inc.Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP effective tax rate non-GAAP | 18.3% | Q1 2026 | — |
| Non-GAAP product gross margin non-GAAP | 87.5% | Q1 2026 | — |
|
|
|||
| Biktarvy U.S. market share | 52% | Q1 2026 call | — |
| U.S. PrEP market growth | 14% | Q1 2026 call | — |
| Yes2Go U.S. access coverage | 95% | Q1 2026 call | — |
| Biktarvy sales | $14.3B | Full Year 2025 | — |
| Cell Therapy product sales | $458M | Q4 2025 | — |
| HIV product sales | $5.8B | Q4 2025 | — |
| Liver Disease portfolio sales | $844M | Q4 2025 | — |
| Product sales excluding Veklury | $7.7B | Q4 2025 | — |
| Veklury sales | $212M | Q4 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GILD
this stock
Gilead Sciences, Inc.
|
$168.45B | +11.7% | +10.0% | 18.5 | 1.9% |
|
LLY
ELI LILLY & Co
|
$1.16T | +15.2% | +44.7% | 43.9 | 1.0% |
|
JNJ
Johnson & Johnson
|
$642.67B | +29.8% | +6.0% | 30.9 | 1.1% |
|
ABBV
AbbVie Inc.
|
$449.91B | +12.3% | +8.6% | 125.4 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$311.31B | +24.2% | +1.4% | 35.5 | 1.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GILD | +7.9% | +5.6% | +11.9% | +7.9% | +11.7% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +7.0% | +4.2% | +4.3% | +7.8% | +2.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.